Aqueous Mushroom Extract and Intraocular Pressure (AME)
Aqueous Mushroom Extract as a Glaucoma Agent
Study Overview
Detailed Description
The Prophet of Islam (Peace Be On Him) was reported to have said that 'mushroom are like manna and their water heals eye diseases'(Sahih Bukhari 1985). This statement is being investigated in view of the link between blood pressure and intra ocular pressure.
Glaucoma which is a sight threatening disease and is associated with raised intraocular pressure has been treated for a long time with beta blockers. Nowadays the drugs of choice are prostaglandin analogs. This study seeks to discover the effect of pleurotus tuberregium on raised intraocular pressure and to compare its effect on I.O.P with that of known glaucoma drugs. This study also seeks to find out at what concentration pleurotus is effective significantly on raised intraocular pressure
Clinical Investigation will be conducted in the Ophthalmological unit of UBTH in two phases. In the first phase 21 relatively young healthy subjects aged less than 50 yrs will be recruited for this study after their informed consent. They will have no previous systemic or ocular diseases and have an intraocular pressure of 19mmHg or less and a visual acuity of 6/6. Base line investigations will include the systolic and diastolic blood pressure, horizontal pupillary diameter and applanation tonometry. The subjects will be divided into three groups of seven each (A1, A2 and A3).
The study will at first constitute two weeks mushroom treatment, two weeks no mushroom treatment and then two weeks mushroom treatment. Treatment will be with aqueous extract of Oyster Medicinal mushroom Extract (4g/100ml) dose: п gutt tid x 1/52 for A1, 2g/100ml dose: п gutt tid x 1/52 for A2 and 1g/100ml dose: п gutt tid x 1/52 for A3. Investigations of the baseline parameters will be done at the start and after each seven days. The subjects will be monitored to ensure full compliance with the designed protocol.
The second phase will involve an equal number of age matched ocular hypertensive or glaucoma patient undergoing treatment in UBTH. They will also be divided into three groups of seven each and the treatment regimen above repeated. The IOP in this case will be taken by a masked observer.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Edo
-
Benin City, Edo, Nigeria
- Eye Clinic University of Benin Teaching Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- clinical diagnosis of open angle glaucoma
- intraocular pressure above 23mmHg
Exclusion Criteria:
- close angle glaucoma
- end stage of glaucoma visual field loss
- ocular disease other than glaucoma that will interfere with result
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: A1 (glaucoma)
|
4g/100ml) dose: п gutt tid x 1/52
(2g/100ml) dose: п gutt tid x 1/52
(1g/100ml) dose: п gutt tid x 1/52
(4g/100ml) dose: п gutt tid x 1/52
|
|
Experimental: A2 (glaucoma)
|
4g/100ml) dose: п gutt tid x 1/52
(2g/100ml) dose: п gutt tid x 1/52
(1g/100ml) dose: п gutt tid x 1/52
(4g/100ml) dose: п gutt tid x 1/52
|
|
Experimental: A3 (glaucoma)
|
4g/100ml) dose: п gutt tid x 1/52
(2g/100ml) dose: п gutt tid x 1/52
(1g/100ml) dose: п gutt tid x 1/52
(4g/100ml) dose: п gutt tid x 1/52
|
|
Experimental: A1 (normals)
|
4g/100ml) dose: п gutt tid x 1/52
(2g/100ml) dose: п gutt tid x 1/52
(1g/100ml) dose: п gutt tid x 1/52
(4g/100ml) dose: п gutt tid x 1/52
|
|
Experimental: A2 (normals)
|
4g/100ml) dose: п gutt tid x 1/52
(2g/100ml) dose: п gutt tid x 1/52
(1g/100ml) dose: п gutt tid x 1/52
(4g/100ml) dose: п gutt tid x 1/52
|
|
Experimental: A3 (normals)
|
4g/100ml) dose: п gutt tid x 1/52
(2g/100ml) dose: п gutt tid x 1/52
(1g/100ml) dose: п gutt tid x 1/52
(4g/100ml) dose: п gutt tid x 1/52
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
DECREASE INTRA OCULAR PRESSURE
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: VINCENT I IYAWE, MD, PhD, University of Benin, Benin City Nigeria
Publications and helpful links
General Publications
- Akinlabi GA, Igbinigie EV, Akpaja EO, Iyawe VI. Preliminary study on the effect of medicinal mushroom extract and timolol maleate on dexamethasone induced ocular hypertension in feline's eye model.Journal of Medicine and Biomedical Research 6(2)63-68. Akinlabi GA, Uzibor HI, Iyawe IO, Iyawe VI. Effect of oyster mushroom exract(pleurotus ostreatus) and latanoprost on intra ocular pressure using cat's eye model. Journal of Medicine and Biomedical Research 8(1)58-64.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MRLLSAW
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.